



Letter to the editor

Hepatocellular carcinoma in Colombia 2017 – 2021



After reviewing the article by Farah *et al.* on the prevalence of hepatocellular carcinoma (HCC) in Latin America [1], we believe that the Colombian experience can be complemented with individual patient care records collected by SISPRO, the official Ministry of Health administrative database [2]. During the five-year period 2017–2021, 2,244 cases of HCC in adult patients were reported nationwide; in contrast to what was reported by Farah *et al.*, females accounted for 49% (n=1,099), a higher figure than 39%. The median age was 68 years, which is similar to what they describe.

With regards to etiology, 520 patients (23.2%) had the associated diagnosis of alcoholic liver disease, and 465 (20.7%) had cryptogenic cirrhosis. On the other hand, in Colombia, there are no recent studies on the prevalence of HCC in patients with autoimmune hepatitis (AIH) or primary biliary cholangitis (PBC). However, a prevalence of 1.6% to 6.6% of HCC in patients with AIH has been described in the United States [3,4]. In this registry, there were 62 cases of HCC associated with autoimmune diseases (2.7% of cases), 9 associated with AIH (0.4%), 23 (1%) with PBC, and 30 (1.3%) associated with sclerosing cholangitis.

With respect to treatment, in their paper, 6% of the patients underwent liver transplantation. The SISPRO registry reports 662 adult liver transplants during this period but does not allow us to uncover their association with HCC. However, we identified 340 patients (15%) of our cohort that were cared for in one of the 7 active authorized liver transplant centers in Colombia, which suggests that at some point they were within the reach of a multidisciplinary team that handles all available alternatives for the treatment of these patients [5].

Administrative databases have the advantage of increasing sample size and, arguably, of having a wider geographical representation than single-center studies. Limitations, of course, have to be highlighted, with the quality of information perhaps the most important one. A growing prevalence of HCC among women, who suffer higher rates of obesity, diabetes and nonalcoholic fatty liver disease, should be a trend to follow closely. We should be thinking about possible alternatives to improve the response provided to HCC [6]. One of these could be the creation of a model focused on liver neoplasms,

similar to the one designed by the Colombian Ministry of Health for the diagnosis and management of Hepatitis C [7].

Declaration of interest

None.

References

- [1] Farah M, Anugwom C, Ferrer JD, Baca EL, Mattos AZ, Possebon JPP, et al. Changing epidemiology of hepatocellular carcinoma in South America: A report from the South American liver research network. *Ann Hepatol* 2022;28(2):100876. <https://doi.org/10.1016/j.aohp.2022.100876>.
- [2] Rosselli D, Pantoja-Ruiz CSISPRO. The administrative database of the Colombian healthcare system. *Acta Neurol Colomb* 2022;38(4):187–90. <https://doi.org/10.22379/24224022426>.
- [3] Yeoman AD, Al-Chalabi T, Karani JB, Quaglia A, Devlin J, Mieli-Vergani G. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: Implications for follow-up and screening. *Hepatology* 2008;48(3):863–70. <https://doi.org/10.1002/hep.22432>.
- [4] Lleo A, de Boer YS, Liberal R, Colombo M. The risk of liver cancer in autoimmune liver diseases. *Ther Adv Med Oncol* 2019;11:1758835919861914. <https://doi.org/10.1177/1758835919861914>.
- [5] Serper M, Taddei TH, Mehta R, D'Addeo K, Dai F, Aytaman A, et al. Association of provider specialty and multidisciplinary care with hepatocellular carcinoma treatment and mortality. *Gastroenterology* 2017;152(8):1954–64. <https://doi.org/10.1053/j.gastro.2017.02.040>.
- [6] Piñero F, Poniachik J, Ridruejo E, Silva M. Hepatocellular carcinoma in Latin America: Diagnosis and treatment challenges. *World J Gastroenterol* 2018;24(37):4224–9. <https://doi.org/10.3748/wjg.v24.i37.4224>.
- [7] Gomez-Aldana AJ, Tapias M, Rosselli D. Colombian experience in the management of hepatitis C. *Liver Int* 2020;40(12):3143. <https://doi.org/10.1111/liv.14582>.

Andres Gomez-Aldana*

Diego Rosselli

Transplant Hepatologist U. Toronto, Clinical Nutrition, McMaster University, Hamilton Canada

Clinical Epidemiology and Biostatistics Department, Pontificia Universidad Javeriana, Medical School, Bogotá, Colombia

*Corresponding author.

E-mail address: andresgomezmd@hotmail.com
(A. Gomez-Aldana).